Ralaniten acetate | Wikipedia audio article
Channel: wikipedia tts
Date: 2018-10-29

This is an audio version of the Wikipedia Article:
Ralaniten acetate

Listening is a more natural way of learning, when compared to reading. Written
language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through
audio (audio article). You could even learn subconsciously by playing the audio
while you are sleeping! If you are planning to listen a lot, you could try using
a bone conduction headphone, or a standard speaker instead of an earphone.


You can find other Wikipedia audio articles too at:
https://www.youtube.com/channel/UCuKfABj2eGyjH3ntPxp4YeQ

In case you don't find one that you were looking for, put a comment.
This video uses Google TTS en-US-Standard-D voice.



SUMMARY
=======
Ralaniten acetate (developmental code name EPI-506) is an experimental nonsteroidal antiandrogen (NSAA) which was developed by ESSA Pharmaceuticals and was under investigation for the treatment of prostate cancer. It was a successor of EPI-001 and targets the N-terminal domain (NTD) of the androgen receptor (AR). This mechanism of action is believed to allow the drug to block signaling from the AR and its splice variants. EPI-506 is a derivative of bisphenol A and a prodrug of ralaniten (EPI-002), one of the four stereoisomers of EPI-001. The drug reached phase I/II prior to the discontinuation of its development. It showed signs of efficacy in the form of prostatic specific antigen (PSA) decreases (4–29%) predominantly at higher doses (≥1,280 mg) in some patients but also caused side effects and was discontinued by its developer in favor of next-generation AR NTD inhibitors with improved potency and tolerability.